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Summary
Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, 
consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed 
to assess whether or not the addition of rindopepimut to standard chemotherapy is able to improve survival in patients 
with EGFRvIII-positive glioblastoma.
Methods In this randomised, double-blind, phase 3 trial, we recruited patients aged 18 years and older with glioblastoma 
from 165 hospitals in 22 countries. Eligible patients had newly diagnosed glioblastoma confirmed to express EGFRvIII 
by central analysis, and had undergone maximal surgical resection and completion of standard chemoradiation 
without progression. Patients were stratified by European Organisation for Research and Treatment of Cancer recursive 
partitioning analysis class, MGMT promoter methylation, and geographical region, and randomly assigned (1:1) with 
a prespecified randomisation sequence (block size of four) to receive rindopepimut (500 µg admixed with 150 µg 
GM-CSF) or control (100 µg keyhole limpet haemocyanin) via monthly intradermal injection until progression or 
intolerance, concurrent with standard oral temozolomide (150–200 mg/m² for 5 of 28 days) for 6–12 cycles or longer. 
Patients, investigators, and the trial funder were masked to treatment allocation. The primary endpoint was overall 
survival in patients with minimal residual disease (MRD; enhancing tumour <2 cm² post-chemoradiation by central 
review), analysed by modified intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01480479.
Findings Between April 12, 2012, and Dec 15, 2014, 745 patients were enrolled (405 with MRD, 338 with significant 
residual disease [SRD], and two unevaluable) and randomly assigned to rindopepimut and temozolomide (n=371) or 
control and temozolomide (n=374). The study was terminated for futility after a preplanned interim analysis. At final 
analysis, there was no significant difference in overall survival for patients with MRD: median overall survival was 
20·1 months (95% CI 18·5–22·1) in the rindopepimut group versus 20·0 months (18·1–21·9) in the control group 
(HR 1·01, 95% CI 0·79–1·30; p=0·93). The most common grade 3–4 adverse events for all 369 treated patients in the 
rindopepimut group versus 372 treated patients in the control group were: thrombocytopenia (32 [9%] vs 23 [6%]), 
fatigue (six [2%] vs 19 [5%]), brain oedema (eight [2%] vs 11 [3%]), seizure (nine [2%] vs eight [2%]), and headache 
(six [2%] vs ten [3%]). Serious adverse events included seizure (18 [5%] vs 22 [6%]) and brain oedema (seven [2%] 
vs 12 [3%]). 16 deaths in the study were caused by adverse events (nine [4%] in the rindopepimut group and seven [3%] 
in the control group), of which one—a pulmonary embolism in a 64-year-old male patient after 11 months of 
treatment—was assessed as potentially related to rindopepimut.
Interpretation Rindopepimut did not increase survival in patients with newly diagnosed glioblastoma. Combination 
approaches potentially including rindopepimut might be required to show efficacy of immunotherapy in glioblastoma.
Funding Celldex Therapeutics, Inc.
Introduction
Glioblastoma is the most common malignant primary 
brain tumour in adults. Its annual incidence is more 
than three per 100 000 people worldwide without 
major regional variation, and men are affected more 
frequently than women.1 The standard of care—maximum 
feasible surgical resection followed by radiotherapy with 
concomitant and maintenance temozolomide chemo­
therapy—generally leads to a median overall survival of 
about 15 months.2,3
The tumour­treating fields device, recently reported to 
extend survival to 20·5 months, represents an additional 
treatment option for glioblastoma.4 Treatment at 
recurrence, which might include second surgery, re­
irradiation, alkylating chemotherapy using nitrosoureas 
such as lomustine or temozolomide rechallenge, or 
antiangiogenic therapy using bevacizumab, is less well 
standardised and has not shown a significant improvement 
in survival in a randomised trial. Poor prognostic factors 
include poor performance status, older age, incomplete 
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resection, and an unmethylated promoter of the DNA 
repair gene, O⁶­methylguanine­DNA methyltransferase 
(MGMT). Novel treatment approaches to glioblastoma are 
therefore urgently needed, and immunotherapy has now 
become the major area of clinical research.
The EGFR gene is amplified in more than 40% of 
glioblastomas, and EGFR amplification is frequently 
associated with a deletion mutation affecting exons 2–7, 
referred to as EGFRvIII or delta­EGFR. EGFRvIII 
expression occurs in roughly 20–30% of all glio­
blastomas.5–7 The potential immunogenicity of the 
EGFRvIII mutation, first recognised several decades ago, 
resulted in the development of rindopepimut—a peptide 
vaccine containing the specific novel aminoacid sequence 
created by the EGFRvIII deletion mutation conjugated to 
keyhole limpet haemocyanin. Rindopepimut has been 
explored in two small single­group phase 2 trials, 
ACTIVATE8 and ACT II,9 as well as a larger phase 2 trial 
ACT III,6 which was initially planned as an open­label, 
randomised phase 3 trial but was converted to a 
single­group design after near­complete voluntary attrition 
of the first 16 patients randomly assigned to receive temo­
zolomide alone. In these trials, about 100 patients with 
EGFRvIII­expressing glioblastoma who had received a 
gross total resection and had no evidence of progression 
after radiotherapy with concomitant temozolomide were 
given rindopepimut alone (ACTIVATE) or rindopepimut 
with adjuvant temo zolomide (ACT II and ACT III). The 
results of these three trials showed a consistent and 
encouraging progression­free survival in the range of 
15 months from diagnosis and overall survival of 
24 months from diagnosis, which compared favourably 
with contemporary patient cohorts who received standard 
treatment (appendix p 8). The selection of patients with 
minimal residual disease (MRD) in all these trials after 
completion of chemoradiation was based on the 
assumption that MRD would minimise the tumour­
associated immuno suppression typical of glioblastoma.
ACT IV was designed as a pivotal, randomised, placebo­
controlled, phase 3 clinical trial to assess whether or not 
Research in context
Evidence before this study
We searched PubMed for scientific literature published in 
English before Aug 1, 2011, using the search terms 
“glioblastoma” and publication type “randomized controlled 
trial” or “clinical trial, phase III”. The standard of care for newly 
diagnosed glioblastoma established in 2005—maximum 
feasible surgical resection followed by radiotherapy and 
temozolomide chemotherapy—is associated with median 
overall survival of about 15 months. Despite the introduction of 
several investigational approaches in the subsequent years, no 
treatment has successfully shown further improvements in 
survival. The addition of the search term “EGFRvIII” and 
expansion of our search to any clinical trial did not identify any 
other agents specifically targeting EGFRvIII. Finally, a search 
including “glioblastoma”, “EGFRvIII”, and “survival” produced a 
few retrospective studies showing similar or worse median and 
long-term survival for patients whose tumour expressed 
EGFRvIII. Three previous studies of rindopepimut have been 
done in patients with newly diagnosed, EGFRvIII-expressing 
glioblastoma and minimal residual disease (MRD). In these 
studies, rindopepimut was associated with a strong 
anti-EGFRvIII humoral immune response, a notable reduction in 
EGFRvIII expression in available recurrent tumour samples, and a 
median survival of 20–22 months, as compared with about 
12 months for a small matched contemporary dataset and 
15 months for the small subset of patients with newly 
diagnosed EGFRvIII-expressing glioblastoma randomly assigned 
to receive standard of care treatment in the ACT III study.
Added value of this study
To our knowledge, ACT IV is the first randomised trial to assess 
the efficacy of an EGFRvIII-targeted treatment for patients with 
newly diagnosed glioblastoma. Despite the strong anti-EGFRvIII 
immune response generated in patients, the primary study 
analysis did not show a survival benefit for patients with MRD 
who received rindopepimut with temozolomide versus those 
who received temozolomide alone. We recorded a potential 
long-term survival benefit in exploratory analyses of a subset of 
patients with significant residual disease (SRD), which might 
challenge the view that minimal tumour burden is required for 
immunotherapy to be effective. Also notable is that patients in 
the control group fared markedly better than matched control 
datasets available at the time of study design, suggesting that 
glioblastoma outcomes have improved since the study was 
originally designed.
Implications of all the available evidence
Our results question the utility of immunotherapy targeting a 
single tumour antigen with heterogeneous tumour expression, 
as well as the optimal setting for evaluation of immunotherapy. 
Patients with more substantial residual disease expressing the 
target antigen might experience greater benefit from generation 
of targeted immunity than those with completely resected 
disease. Recent data from a randomised, double-blind, phase 2 
study in recurrent EGFRvIII-positive glioblastoma (the ReACT 
study) suggest a prominent treatment effect (overall survival 
HR 0·53, 95% CI 0·32–0·88; p=0·013) for rindopepimut when 
combined with standard bevacizumab versus bevacizumab 
alone. Its combination with temozolomide might compromise 
an immunological effect, by contrast with bevacizumab. The 
results of ACT IV also question the predictive value of both 
historical control datasets (matched patients from non-study 
databases) and small randomised phase 2 trial datasets (such as 
ACT III) as a basis for the design of phase 3 studies. These data 
lend support to further clinical trials that use combination 
strategies such as immunotherapy with angiogenesis inhibition.
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the addition of rindopepimut to standard temozolomide 
chemotherapy increased overall survival compared with 
that for temozolomide alone in patients with newly 
diagnosed EGFRvIII­expressing glioblastoma.
Methods
Study design and participants
ACT IV was a randomised, double­blind, phase 3 study 
done at 165 hospitals in 22 countries (appendix p 12). The 
study was open to men and women aged 18 years and 
older with newly diagnosed EGFRvIII­expressing glio­
blastoma. Confirmation of glioblastoma histology and 
EGFRvIII expression analysis from resected tissue by real­
time (RT) PCR were done centrally (LabCorp, Research 
Triangle Park, NC, USA). Patients must have undergone 
maximal surgical resection and have completed standard 
radiotherapy (up to 60 Gy) with concomitant temozolomide 
(75 mg/m² per day).2 To be eligible, at least 90% of the 
planned radiotherapy dose had to be delivered. Patients 
had to have tumour tissue specimens (paraffin­embedded) 
from surgical resection available for central pathology 
review, MGMT status determination, and analysis of 
EGFRvIII status. Exclusion criteria were disease 
progression during chemoradiation, any additional 
tumour­specific treatment for glioblastoma, inability to 
taper corticosteroids to 2 mg of dexamethasone or lower 
(or equivalent) per day for at least 3 days before 
randomisation, Eastern Cooperative Oncology Group 
(ECOG) performance status of 3 or higher in the week 
before randomisation, diffuse leptomeningeal disease, 
gliomatosis cerebri, infratentorial disease, active infection, 
metastatic disease, and immunosuppressive disease.
An independent imaging review committee (BioClinica, 
Princeton, NJ, USA) assessed post­operative and post­
chemoradiation brain MRIs, and retrospectively classified 
patients as having either MRD (<2 cm² of residual 
enhancing tumour on post­chemoradiation imaging) or 
significant residual disease (SRD; ≥2 cm² of residual 
enhancing tumour on post­chemoradiation imaging).
The study was compliant with the Declaration of 
Helsinki and Good Clinical Practice guidelines. Ethics 
approval was obtained at all participating centres and all 
patients provided written informed consent. The full trial 
protocol can be found in the appendix.
Randomisation and masking
Eligible patients were stratified by MGMT promoter 
methylation status (methylated vs unmethylated vs 
unknown), European Organisation for Research and 
Treatment of Cancer (EORTC) recursive partitioning 
analysis class (III vs IV vs V),10,11 and geographical region 
(North America and western Europe vs all other regions), 
and were randomly assigned (1:1) to the treatment groups 
with a prespecified randomisation sequence with a block 
size of four. Unblinded pharmacists who were otherwise 
uninvolved in study conduct obtained randomly assigned 
treatment assignments and managed study treatment via 
interactive response technology. Study treatments were 
prepared in the pharmacy and given to study staff in 
blinded (label included patient ID and expiry information), 
pre­loaded syringes. Keyhole limpet haemocyanin was 
given as a control injection to produce a local reaction 
similar to that expected with rindopepimut to maintain 
the treatment blind. Pharmacovigilance staff at the study 
funder and contract research organisation received 
treatment assignments for individual patients when 
necessary to comply with international safety reporting. 
Pharmacy records were audited by an independent team 
of contract research organisation staff. The study data 
monitoring committee and the supportive independent 
statistical group at the contract research organisation 
viewed unblinded data. All other study staff, patients, and 
investigators remained masked to treatment assignments.
Procedures
All patients received standard maintenance temozolomide 
administered orally at a dose of 150–200 mg/m² on 
days 1–5 of each 28­day cycle, for 6–12 cycles,2 or longer if 
consistent with the local standard of care. Patients 
randomly assigned to the rindopepimut group also 
received 500 µg of rindopepimut admixed with 150 µg 
GM­CSF (Leukine, Sanofi Aventis, Bridgewater, NJ, USA), 
while the control group received 100 µg keyhole limpet 
haemocyanin (Biosyn, Carlsbad, CA, USA). Each 0·8 mL 
dose was given as two to eight separate intradermal 
injections into the skin of the thigh below the groin. The 
allowance for between two and eight injections allowed 
for a smaller volume of individual intradermal injections, 
potentially reducing patient discomfort and risk of 
leakage. Experimental treatment was started 7–14 days 
after completion of standard chemoradiation, and was 
given as two initial priming doses (on study days 1 and 15), 
then monthly on day 22 of each temozolomide cycle and 
continuing after the end of maintenance temozolomide 
until disease progression or intolerance. Because all 
toxicities related to rindopepimut vaccination were 
expected to be immunologically mediated, no adjustment 
to the dose of double­blind vaccine was allowed; however, 
dose omission or delay was allowed for toxicity.
Brain MRI scans were done within 14 days after 
completion of chemoradiation, every 8 weeks for 
6 months, every 12 weeks from 6 months through year 2, 
every 16 weeks from years 2–4, and every 26 weeks 
thereafter, or until documented disease progression. 
Tumour response and progression were assessed 
according to the Response Assessment in Neuro­
Oncology (RANO) Working Group criteria,12 with 
minor modifications for the purpose of protocol standard­
isation (appendix p 9). Local investigator assessments 
guided individual treatment decisions. The retrospective 
imaging review committee assessment, masked to 
treatment assignment and investigator assessments, was 
used for the primary analyses of progression­free survival 
and objective tumour response.
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Safety assessments included monthly physical 
examination, vital signs, routine laboratory monitoring 
(haematology on days 1 and 22 of each cycle, and blood 
chemistry and urinalysis on day 1 of each cycle), and 
evaluation of adverse events using National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (CTCAE; version 4.0). The MD Anderson 
Symptom Inventory Brain Tumor (MDASI­BT) and 
EORTC Core Quality of Life Questionnaire (QLQ­C30) 
and Brain Cancer Module (BN20) were completed every 
month throughout treatment by patients who were fluent 
in a language in which the questionnaires were validated.
To assess EGFRvIII expression, formalin­fixed paraffin­
embedded tumour tissue was analysed centrally (LabCorp, 
Research Triangle Park, NC, USA). EGFRvIII variant and 
EGFR wild­type status were ascertained with a Taqman­
based RT­PCR assay done on an ABI Prism (Applied 
Biosystems Corporation, Foster City, CA, USA) 7900HT 
instrument. The fluorescence detected was directly 
proportional to the amount of RNA present and expressed 
as cycle threshold. We used a predefined cutoff expressed 
as delta cycle threshold (cycle threshold of EGFRvIII 
minus that of EGFR wild type) of 11·0 or lower to define a 
sample as positive for EGFRvIII. The threshold, which 
was selected as a conservative cutoff to minimise the 
possibility of including EGFRvIII­negative patients, was 
defined by the delta cycle threshold values of samples 
from the ACT III study that showed unambiguous calls of 
positive (n=9) or negative (n=10) by corroboration of 
immunohistochemistry and PCR results, confirmed by 
reproducibility testing and accuracy verification.
To assess MGMT promoter methylation status, 
formalin­fixed paraffin­embedded tumour samples were 
analysed centrally at LabCorp under licence from MDx 
Health (Irvine, CA, USA) by methylation­specific PCR, 
based on previously published methods.13
To assess humoral responses to the vaccine, antibody 
titres were measured by ELISA with microtitre plates 
directly coated with a 14­aminoacid peptide, which spans 
the exons 1–8 junction of EGFR and is specific for the 
EGFRvIII mutant.14 Dilutions of patient plasma were 
incubated in the plates, and the anti­EGFRvIII antibodies 
were detected with an Fc­γ­specific goat anti­human 
F(abʹ)2 antibody conjugated to horseradish peroxidase 
(Jackson ImmunoResearch Labs, West Grove, PA, USA) 
followed by tetra­methylbenzidine substrate. Absorbance 
was measured at wavelength of 450 nm. Patient samples 
were screened and positive samples titred against a plate­
specific floating cutoff point. We calculated the antibody 
titre for patient samples as the highest dilution with an 
optical density value greater than the mean plus three 
times the standard deviation (SD) of replicate­negative 
control samples run on the same plate. Because the 
starting dilution was 1:100, we reported samples that 
screened negative with titres lower than 1:100. For post­
hoc exploratory analyses of survival, patients were 
retrospectively classified according to the trajectory at 
which anti­EGFRvIII titres developed with rindopepimut 
treatment (slow, moderate, or rapid).
Typing of HLA class I alleles (A and B loci) 
and HLA class II alleles (with a –DR locus) by serology 
or DNA­PCR was done by an American Society for 
Histocompatibility and Immunogenetics­accredited 
laboratory (ClinImmune Labs, Aurora, CO, USA) using 
buccal swab samples.
Outcomes
The primary endpoint was overall survival (defined as the 
time from randomisation to death) in patients with newly 
diagnosed, EGFRvIII­positive glioblastoma and MRD. 
Patients with SRD formed a second exploratory cohort 
that had not been included in previous studies; overall 
survival was assessed in these patients and in the entire 
patient cohort (all randomised patients) as supportive 
secondary analyses. Secondary endpoints were 
progression­free survival (defined as the time from 
randomisation to disease progression or death, whichever 
occurred first), the proportion of patients achieving an 
objective tumour response (a confirmed complete or 
partial response according to the RANO criteria), health­
related quality of life (assessed with the MDASI­BT, 
QLQ­C30, and BN20), and to further characterise the 
safety profile and overall immunogenicity of rindopepimut 
in patients with both MRD and SRD. Correlative endpoints 
were the specific humoral responses to EGFRvIII and 
post­treatment EGFRvIII expression status.
Statistical analysis
Patients classified with MRD by the imaging 
review committee were included in the modified 
intention­to­treat population for the primary analysis of 
overall survival. 283 deaths in the MRD population at the 
time of the final analysis were calculated to provide 
80% power to detect a target hazard ratio (HR) of 0·714, 
which corresponded to a 6­month improvement in 
median overall survival (from 15 months for the control 
group to 21 months for the rindopepimut group). The 
target number of deaths was based on a one­sided log­
rank test, overall type I error rate of 0·025, and 
two planned interim analyses of overall survival for 
superiority using an O’Brien­Fleming group sequential 
monitoring plan. Allowing for a 48­month accrual period 
and 10% attrition rate, a sample size of 374 patients with 
MRD was expected to result in 283 deaths within 
72 months of the first randomly assigned patient. 
Supportive secondary analyses of overall survival were 
done for all randomly assigned patients (intention­to­
treat analysis). To control the family­wise error rate (the 
probability of making one or more false discoveries when 
performing multiple hypotheses tests), study analyses 
were to proceed according to a fixed sequence procedure 
in which the primary analysis was completed for the 
MRD population (modified intention to treat) and 
all enrolled patients (intention to treat) sequentially, 
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followed by the secondary endpoint analyses (appendix 
p 1). According to this analysis plan, each sequential 
statistical test was to be considered positive only if the 
previous statistical test was positive. The sample size for 
patients with SRD was not prospectively defined, and 
analysis of this population was planned as exploratory. 
Safety analyses included patients who received at least 
one dose of study treatment.
Overall survival and progression­free survival, including 
landmark survival rates at 1, 2, and 3 years, were 
summarised using the Kaplan­Meier method. For overall 
survival, patients who were still alive or lost to follow­up at 
the data analysis cutoff date were right­censored. The 
censoring date was defined as the patients’ date of last 
contact or data analysis cutoff date (whichever occurred 
first). Primary inferential comparisons between treatment 
Figure 1: Trial profile
*Reasons for failure to enrol were collected via a hard copy screening log, with data for 304 of these 600 patients compiled electronically at the time of study closure. Of these, 143 (47%) declined study 
participation, 68 (22%) experienced disease progression before study entry, 21 (7%) had a contraindicated concurrent illness or low Eastern Cooperative Oncology Group performance status, 11 (4%) 
did not receive adequate or standard chemoradiation, 11 (4%) were not candidates for adjuvant temozolomide, ten (3%) were receiving exclusionary doses of corticosteroid, and 40 (13%) were not 
enrolled for other miscellaneous reasons. GBM=glioblastoma.
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groups used the log­rank test stratified by MGMT 
promoter methylation status, adapted recursive 
partitioning analysis class, and geographical region. HRs 
were estimated using a stratified Cox proportional hazards 
model. The proportion of patients who achieved an 
objective tumour response was summarised for all 
patients with measurable, enhancing tumour on post­
chemo radiation MRI per imaging review committee 
assess ment (ie, the response evaluable population). 
Subgroup analyses were planned according to age, sex, 
race, MGMT status, recursive partitioning analysis class, 
geographical region and baseline tumor burden by 
investigator assessment (ie, measurable target lesions 
<2  cm² or ≥2 cm² per RANO). 
For diagnostic purposes, the overall survival proportional 
hazard assumption was checked by comparing the HRs 
and assessing the significance level of stratification 
variables from stratified and unstratified Cox models. We 
explored the interactions between the treatment group 
and stratification variables by inclusion of the stratification 
factors as covariates in the unstratified Cox model. In 
recognition of the delayed treatment effect previously 
recorded with other immunotherapies, an exploratory 
analysis using a weighted log­rank test was also done.15 In 
exploratory correlation analyses of HLA type and outcome, 
the overall survival and progression­free survival hazard 
ratio was calculated between treatment groups within 
each HLA type, with p value based on type 3 test from Cox 
model with treatment group, HLA type, and treatment 
group * HLA type interaction as covariates. 
We planned two interim analyses for superiority and 
futility after 142 and 212 deaths in the MRD population, 
representing 50% and 75% of the events required for final 
analysis. The study was designed with a non­binding 
approach for efficacy and futility boundaries. Early 
stopping boundaries for superiority according to an 
O’Brien­Fleming alpha spending were a p value of 0·002 
for the first interim analysis and a p value of 0·018 for the 
second interim analysis. The futility analyses were based 
on the observed treatment effect, with HRs of 1·1 or higher 
and higher than 0·9, respectively, representing boundaries 
for futility for the two interim analyses. For the first and 
second interim analyses, respectively, the chances of 
stopping a positive study for futility were 0·5% and 4·6% 
and the chances of stopping a negative study for futility 
were 29% and 78%, respectively. The data monitoring 
committee evaluated the preplanned interim analyses. 
SAS version 9.4 was used for all statistical analyses. 
This study is registered with ClinicalTrials.gov, number 
NCT01480479.
MRD population 
(primary analysis population)
Intention-to-treat population 
(all randomly assigned patients)
SRD population
Rindopepimut plus 
temozolomide 
(n=195)
Control plus 
temozolomide 
(n=210)
Rindopepimut plus 
temozolomide 
(n=371)
Control plus 
temozolomide 
(n=374)
Rindopepimut plus 
temozolomide 
(n=175)
Control plus 
temozolomide 
(n=163)
Age (years) 59 (51–64) 57 (51–64) 59 (51–64) 58 (52–64) 58 (51–64) 59 (52–64)
Age ≥65 years 46 (24%) 50 (24%) 87 (23%) 87 (23%) 40 (23%) 37 (23%)
Sex
Male 133 (68%) 121 (58%) 252 (68%) 228 (61%) 118 (67%) 106 (65%)
Female 62 (32%) 89 (42%) 119 (32%) 146 (39%) 57 (33%) 57 (35%)
ECOG performance status
0 100 (51%) 102 (49%) 165 (45%) 168 (45%) 65 (37%) 65 (40%)
1 86 (44%) 97 (46%) 188 (51%) 185 (50%) 101 (58%) 88 (54%)
2 9 (5%) 11 (5%) 18 (5%) 21 (6%) 9 (5%) 10 (6%)
MGMT promoter status
Methylated 69 (35%) 73 (35%) 124 (33%) 130 (35%) 55 (31%) 57 (35%)
Unmethylated 107 (55%) 119 (57%) 224 (60%) 218 (58%) 116 (66%) 98 (60%)
Unknown 19 (10%) 18 (9%) 23 (6%) 26 (7%) 4 (2%) 8 (5%)
Recursive partitioning analysis class
III 25 (13%) 27 (13%) 46 (12%) 37 (10%) 21 (12%) 9 (6%)
IV 139 (71%) 157 (75%) 256 (69%) 274 (73%) 116 (66%) 117 (72%)
V 31 (16%) 26 (12%) 69 (19%) 63 (17%) 38 (22%) 37 (23%)
Time from diagnosis to 
randomisation (months)
2·8 (2·6–3·1) 2·8 (2·6–3·1) 2·9 (2·6–3·2) 2·8 (2·6–3·1) 2·9 (2·7–3·2) 2·9 (2·7–3·2)
Previous radiotherapy dose (Gy) 60 (60–60) 60 (60–60) 60 (60–60) 60 (60–60) 60 (60–60) 60 (60–60)
Previous temozolomide dose 
(mg/m²)
3225 
(3150–3300)
3225 
(3150– 3375)
3225 
(3150–3300)
3225 
(3150–3375)
3225 
(3150–3375)
3225 
(3150–3375)
Data are median (IQR) or n (%). MRD=minimal residual disease. SRD=significant residual disease. ECOG=Eastern Cooperative Oncology Group. MGMT=O6-methylguanine-DNA 
methyltransferase.
Table 1: Baseline characteristics
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Role of the funding source
The funder designed the study in collaboration with the 
investigators, managed the clinical trial database 
including oversight of data collection, performed 
statistical analyses, and provided medical writing 
assistance. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Jan 26, 2012, and Dec 1, 2014, 4652 patients were 
screened for study eligibility (figure 1). In the cohort of 
4519 patients for whom submitted tumour tissue was 
adequate for EGFRvIII expression analysis, 1345 (30%) 
had EGFRvIII­expressing tumours. Between April 12, 
2012, and Dec 15, 2014, 745 eligible patients with 
EGFRvIII­expressing tumours were randomly assigned 
to receive rindopepimut (n=371) or control (n=374). 
Of these, 405 (195 allocated to rindopepimut and 
210 allocated to control) were assigned to the MRD 
population by central review and included in the primary 
modified intention­to­treat analysis, and 741 (369 allo­
cated to rindopepimut and 372 allocated to control) 
received at least one dose of study treatment and were 
included in the safety analyses. 338 patients (175 allocated 
to rindopepimut and 163 allocated to control) had SRD 
and two were unevaluable (one allocated to each group). 
Pretreatment patient and disease characteristics for 
randomly assigned patients were well balanced between 
treatment groups within each analysis population 
(table 1).
At the second preplanned interim analysis done after 
212 deaths had occurred in the MRD population (data 
cutoff Oct 24, 2015), the futility boundary was crossed. The 
overall survival HR for rindopepimut versus control in the 
MRD population was 0·99 (95% CI 0·74–1·31), suggesting 
that rindopepimut was unlikely to be better than the 
control in terms of overall survival. Therefore, the study 
was closed prematurely, and preliminary primary analysis 
results were released. Additional survival information was 
obtained as patients were discontinued from the study, and 
final analyses were done with a data cutoff of April 29, 2016. 
At study closure and final analysis, 523 deaths (254 in the 
rindopepimut group [129 in the MRD population] and 
269 in the control group [135 in the MRD population]) and 
546 progression events (267 in the rindopepimut group 
[141 in the MRD population] and 279 in the control 
group [149 in the MRD population]) had occurred.
Overall survival did not differ between the treatment 
groups for the MRD or intention­to­treat populations 
(figure 2A, 2B). Median overall survival in the 
rindopepimut group was 20·1 months (95% CI 18·5–22·1) 
versus 20·0 months (18·1–21·9) in the control group in 
the MRD population (HR 1·01, 95% CI 0·79–1·30; 
p=0·93), and 17·4 months (16·1–19·4) versus 17·4 months 
(16·2–18·8), respectively, in the intention­to­treat 
population (HR 0·89, 95% CI 0·75–1·07; p=0·22). In an 
exploratory analysis of the SRD population (HR 0·79, 
95% CI 0·61–1·02; p=0·066), median overall survival was 
similar between the treatment groups (14·8 months 
Figure 2: Overall survival
Overall survival in (A) the minimal residual disease (primary analysis) population, (B) the intention-to-treat 
population, and (C) the significant residual disease population. HR=hazard ratio.
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[95% CI 12·8–17·1] in the rindopepimut group vs 
14·1 months [12·6–15·7] in the control group; figure 2C).
In the group of patients who were classified with 
MRD or SRD by investigator assessment (rather than 
the central reviewer), overall survival also did not 
differ between treatment groups (appendix p 2). We also 
performed prespecified and post­hoc subgroup analyses 
of overall survival in the MRD and SRD populations; the 
findings of these subgroup analyses were consistent with 
our main findings (figure 3).
However, in an exploratory prespecified analysis in the 
SRD population a difference in long­term survival was 
recorded, with a 2­year overall survival of 30% (95% CI 
23–37) in the rindopepimut group versus 19% (13–26) in 
the control group (p=0·029). However, this difference 
was not significant when SRD was classified by 
investigator assessment rather than by central review 
(appendix p 2).
On sensitivity analysis of overall survival, we noted 
some violations of the proportional hazard assumption in 
various strata (data not shown). We explored interactions 
between the treatment group and stratification variables 
and found that none of the interaction terms were 
significant (data not shown). The weighted log­rank p 
values for prespecified weights (r1=0, r2=1, 2) were 0·93 
and 0·88 for the MRD population, 0·081 and 0·092 for 
the intention­to­treat population, and 0·021 and 0·017 for 
the SRD population, respectively.
The median duration of adjuvant temozolomide 
treatment within the MRD population was 5·2 months 
(IQR 3·2–10·3) for the rindopepimut group versus 
5·0 months (3·0–10·1) for the control group. The 
median duration of adjuvant temozolomide within the 
SRD population was 4·1 months (IQR 2·0– 7·3) for 
the rindopepimut group versus 4·1 months (2·0–6·7) 
for the control group. Anticancer treatments given in 
the post­treatment follow­up were well balanced across 
treatment groups (appendix p 10), although we noted 
some geographical differences in the type of anticancer 
treatments used after progression (appendix p 11), with 
more frequent use of nitrosoureas in the European 
Union and more frequent use of bevacizumab in 
the USA.
Progression­free survival was similar between 
treatment groups within the MRD (median progression­
free survival 8·0 months, 95% CI 7·1–8·5, in the 
rindopepimut group vs 7·4 months, 6·0–8·7, in the 
control group; HR 1·01, 95% CI 0·80–1·29; p=0·91), 
intention­to­treat (7·1 months, 5·4–7·9 vs 5·6 months, 
5·1–7·1; 0·94, 0·79–1·13; p=0·51), and SRD (3·7 months, 
3·5–5·8 vs 3·7 months, 3·3–4·9; 0·86, 0·66–1·12; 
p=0·28) populations (appendix p 3). The proportion of 
patients who achieved an objective tumour response in 
the response­evaluable population irrespective of MRD or 
SRD status did not differ between treatment groups 
(31 [15%, 95% CI 10–21] of 208 in the rindopepimut group 
and 27 [15%, 95% CI 10–21] of 184 in the control group).
We noted no significant differences between groups in 
any of the quality­of­life measures (appendix p 4) or 
requirement for corticosteroids (which formed a part of 
response assessment) in the analysis populations 
(appendix p 5).
Rindopepimut treatment led to robust humoral 
responses, with treated patients reaching a median 
peak anti­EGFRvIII antibody titre of 1:25 600 
(IQR 3200–204 800). The magnitude of response was 
similar between the MRD and SRD populations (appendix 
p 6). The use of corticosteroids did not seem to have a 
substantial effect on the rindopepimut­induced humoral 
immune response (appendix p 7). However, we did not 
record a consistent association between increasingly 
rapid titre response and clinical outcome (figure 3).
Intensity of tumour EGFRvIII expression (RT­PCR 
delta cycle threshold in the baseline sample) was not 
associated with outcome (figure 3). In the small subset 
of patients with available post­treatment tumour sample, 
EGFRvIII expression established by RT­PCR was 
undetectable after treatment for 21 (57%) of 37 patients 
given rindopepimut and 23 (59%) of 39 patients in the 
control group. Mean anti­EGFRvIII titre did not differ 
significantly between the groups of patients with either 
loss or persistence of tumour EGFRvIII (data not 
shown). Elimination of EGRFvIII was not associated 
with with outcome (data not shown).
Correlation analysis of HLA type with outcome was 
done for the MRD and SRD populations. Although B18, 
A25, and D11 were each associated with overall survival 
or progression­free survival in individual analyses, 
sample sizes were small, this association was not 
observed consistently in the analysis populations, and 
these HLA types would not be predicted to bind to the 
EGFRvIII peptide based on algorithm analysis of the 
peptide (data not shown).
Rindopepimut was very well tolerated (table 2). 
Injection­site reactions, consisting mainly of transient 
grade 1–2 erythema, pruritus, and rash, were reported for 
most patients who received rindopepimut (294 [80%] 
of 369), but were also common in the control group 
(151 [41%] of 372). The most common grade 3–4 adverse 
events for all 369 treated patients in the rindopepimut 
group versus 372 patients in the control group were: 
thrombocytopenia (32 [9%] vs 23 [6%]), fatigue (six [2%] 
vs 19 [5%]), brain oedema (eight [2%] vs 11 [3%]), seizure 
(nine [2%] vs eight [2%]), and headache (six [2%] 
vs ten [3%]). The most common serious adverse events 
were seizure (18 [5%] vs 22 [6%]) and brain oedema 
(seven [2%] vs 12 [3%]). Of the 523 reported deaths, most 
(427 [82%]) were due to disease progression (204 [80%] 
of 254 in the rindopepimut group and 223 [83%] of 269 in 
the control group), 80 were due to other or unknown 
causes (41 [16%] in the rindopepimut group and 39 [14%] 
in the control group), and 16 were due to adverse events 
(9 [4%] in the rindopepimut group and seven [3%] in the 
control group). One death—a pulmonary embolism in a 
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64­year­old male patient after 11 months of treatment—
was assessed as potentially related to rindopepimut. 
Eight patients discontinued vaccine treatment due to 
treatment­related toxic effects. These included two cases 
of hypersensitivity or allergic reaction, two cases of rash, 
and single cases of bone or muscle pain and the fatal 
pulmonary thromboembolism in the rindopepimut 
group, and single cases of rash and depression in the 
control group. Despite the finding of hypersensitivity 
reaction attributed to rindopepimut in previous 
Figure 3: Subgroup analyses of overall survival
HR=hazard ratio. MRD=minimal residual disease. SRD=significant residual disease. RPA=recursive partitioning analysis. HRs were calculated for the patients given rindopepimut within each classification versus 
all patients in the control group.*The fluorescence detected was directly proportional to the amount of RNA present and expressed as cycle threshold. EGFRvIII intensity is defined by delta cycle 
threshold (cycle threshold of EGFRvIII minus that of EGFR wild type). †Humoral response was classified according to the trajectory at which anti-EGFRvIII titres developed with rindopepimut treatment.
Rindopepimut
MRD population (events/patients)
Control
HR (95% CI) p value
Rindopepimut Control
HR (95% CI) p value
Country
USA
Other
Age
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≥65 years
Sex
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Female
Race
White
Other
MGMT status
Methylated
Unmethylated
RPA class
III
IV
V
EGFRvIII intensity*
≤0·5
0·5–4·24
>4·24
Humoral response†
Slow
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Rapid
Subsequent therapy
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Bevacizumab
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Other chemotherapy
All patients
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 53/75
 98/149
 31/46
 88/133
 41/62
 115/176
 14/19
 31/69
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 37/58
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 45/59
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 29/36
 26/34
 129/195
 86/133
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 99/160
 36/50
 79/121
 56/89
 123/193
 12/17
 33/73
 92/119
 17/27
 98/157
 20/26
 38/64
 52/76
 45/70
 135/210
 135/210
 135/210
 39/51
 74/94
 39/51
 28/40
 28/31
 135/210
1·02 (0·75–1·41)
1·00 (0·65–1·54)
0·97 (0·72–1·31)
1·21 (0·71–2·06)
1·01 (0·73–1·39)
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1·19 (0·73–1·92)
1·02 (0·64–1·64)
1·09 (0·81–1·47)
0·69 (0·41–1·19)
1·13 (0·70–1·82)
1·12 (0·79–1·59)
1·07 (0·62–1·85)
1·05 (0·56–1·94)
0·60 (0·32–1·15)
1·01 (0·79–1·30)
0·89
0·99
0·86
0·48
0·97
0·73
0·89
0·69
1·0
0·78
0·30
0·72
0·77
0·94
0·64
0·49
0·93
0·56
0·18
0·61
0·54
0·81
0·89
0·12
0·92
 78/111
 46/64
 93/135
 31/40
 87/118
 37/57
 111/155
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 14/21
 82/116
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0·83 (0·49–1·40)
0·87 (0·55–1·38)
0·81 (0·50–1·31)
0·92 (0·58–1·46)
1·10 (0·73–1·66)
0·57 (0·39–0·83)
1·01 (0·63–1·63)
0·66 (0·31–1·44)
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0·49 (0·25–0·97)
0·90 (0·46–1·75)
1·66 (0·61–4·51)
0·79 (0·61–1·02)
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0·76
0·20
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0·20
0·27
0·11
0·91
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0·066
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Favours control 
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1
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studies,6,8,9 such events were infrequent in both treatment 
groups in this study (table 2). Similary, no evidence 
suggested increased toxicities that might theoretically 
have arisen due to rindopepimut­induced immune 
infiltration of the brain, such as cerebral oedema or 
seizure (table 2).
Discussion
The primary analysis of the ACT IV study did not show a 
survival benefit for patients with EGFRvIII­positive 
glioblastoma with MRD who received rindopepimut with 
temozolomide versus those who received a control. 
Notably, the definition for MRD was increased to less than 
2 cm² of residual enhancing tumour in the ACT IV study, 
as compared with 1 cm² or less in previous studies. Median 
overall survival from randomisation for patients with MRD 
given rindopepimut in ACT IV was 20·1 months, which is 
consistent with the range of 20–22 months recorded in 
previous uncontrolled trials in the same population.6,8,9 
However, patients in the control group fared substantially 
better than matched control datasets available at the time 
of study design (appendix p 8).
Rindopepimut plus temozolomide (n=369) Control plus temozolomide (n=372)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Injection-site reaction 294 (80%) 0 0 0 151 (41%) 0 0 0
Fatigue 133 (36%) 6 (2%) 0 0 125 (34%) 19 (5%) 0 0
Nausea 128 (35%) 3 (1%) 0 0 132 (36%) 5 (1%) 0 0
Headache 122 (33%) 5 (1%) 1 (<1%) 0 107 (29%) 10 (3%) 0 0
Thrombocytopenia 66 (18%) 21 (6%) 11 (3%) 0 75 (20%) 14 (4%) 9 (2%) 0
Constipation 86 (23%) 3 (1%) 0 0 91 (25%) 3 (1%) 0 0
Vomiting 75 (20%) 2 (1%) 0 0 76 (20%) 4 (1%) 0 0
Decreased appetite 67 (18%) 4 (1%) 0 0 78 (21%) 1 (<1%) 0 0
Dizziness 56 (15%) 2 (1%) 0 0 69 (19%) 2 (1%) 0 0
Seizure 48 (13%) 7 (2%) 2 (1%) 0 61 (16%) 7 (2%) 1 (<1%) 0
Insomnia 55 (15%) 1 (<1%) 0 0 48 (13%) 0 0 0
Rash 43 (12%) 3 (1%) 0 0 68 (18%) 5 (1%) 0 0
Neutropenia 27 (7%) 12 (3%) 7 (2%) 0 16 (4%) 9 (2%) 8 (2%) 0
Lymphopenia 26 (7%) 17 (5%) 2 (1%) 0 24 (6%) 9 (2%) 3 (1%) 0
Muscular weakness 39 (11%) 5 (1%) 0 0 39 (11%) 12 (3%) 0 0
Diarrhoea 43 (12%) 0 0 0 64 (17%) 0 0 0
Depression 36 (10%) 4 (1%) 0 0 47 (13%) 2 (1%) 1 (<1%) 0
Back pain 35 (10%) 2 (1%) 0 0 38 (10%) 3 (1%) 0 0
Peripheral oedema 33 (9%) 2 (1%) 0 0 43 (12%) 0 0 0
Pruritus 34 (9%) 0 0 0 55 (15%) 1 (<1%) 0 0
Aphasia 28 (8%) 4 (1%) 2 (1%) 0 41 (11%) 11 (3%) 0 0
Anxiety 31 (8%) 1 (<1%) 0 0 44 (12%) 0 0 0
Gait disturbance 28 (8%) 2 (1%) 0 0 36 (10%) 5 (1%) 0 0
Arthralgia 30 (8%) 0 0 0 46 (12%) 1 (<1%) 0 0
Pyrexia 23 (6%) 1 (<1%) 0 0 37 (10%) 0 0 0
Brain oedema 9 (2%) 3 (1%) 5 (1%) 0 9 (2%) 4 (1%) 7 (2%) 0
Hypersensitivity 7 (2%) 1 (<1%) 0 0 5 (1%) 0 0 0
Other nervous system disorders 145 (39%) 33 (9%) 4 (1%) 2 (1%) 175 (47%) 32 (9%) 1 (0.3%) 2 (1%)
Infections and infestations 117 (32%) 19 (5%) 3 (1%) 0 130 (35%) 21 (6%) 2 (1%) 1 (<1%)
Respiratory, thoracic, and 
mediastinal disorders
89 (24%) 7 (2%) 4 (1%) 3 (1%) 96 (26%) 5 (1%) 3 (1%) 0
Other gastrointestinal disorders 85 (23%) 6 (2%) 1 (<1%) 1 (<1%) 89 (24%) 10 (3%) 0 0
Other musculoskeletal and 
connective tissue disorders
89 (24%) 3 (1%) 0 0 96 (26%) 8 (2%) 0 0
Other investigations 68 (18%) 14 (4%) 3 (1%) 0 85 (23%) 9 (2%) 3 (1%) 0
Other general disorders and 
administration-site conditions
73 (20%) 8 (2%) 0 0 80 (22%) 13 (3%) 0 2 (1%)
Injury, poisoning, and procedural 
complications
67 (18%) 8 (2%) 1 (<1%) 1 (0.3%) 69 (19%) 9 (2%) 1 (<1%) 0
Other psychiatric disorders 64 (17%) 9 (2%) 1 (<1%) 0 64 (17%) 8 (2%) 1 (<1%) 1 (<1%)
(Table 2 continues on next page)
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In view of the previous ACT III study in which 
voluntary attrition of patients randomly assigned to the 
open­label control group rendered the original 
randomised design infeasible, we recognised that a truly 
blinded design would be crucial for ACT IV. Therefore, 
rather than an inactive placebo, we used keyhole limpet 
haemocyanin as a control injection to replicate the local 
reactions (erythema, pruritus, and rash) experienced by 
nearly all patients who receive rindopepimut. Keyhole 
limpet haemocyanin can generate immune activation 
and one might speculate that the better than expected 
outcome in the control group might result from the 
generation of an effective immune response unrelated to 
EGFRvIII. However, it is generally thought that a tumour­
specific response triggered by keyhole limpet haemo­
cyanin would require topical application to the tumour 
itself (intratumoural injection in this case) and that a 
genuine therapeutic effect is unlikely to result from 
peripheral intradermal injection. In a small phase 2 trial 
of patients with recurrent disease (ReACT),16 the same 
keyhole limpet haemocyanin control was used with 
control group outcome no better than expected. The 
unexpectedly favourable outcome for the ACT IV control 
group might also have resulted from enrolment of lower 
risk patients (ie, patients with favourable prognostic 
factors) compared with previous trials. However, the 
eligibility criteria and baseline characteristics of patients 
in the ACT IV study were similar to the previous phase 2 
studies of rindopepimut.6,8,9 Additionally, ACT IV was a 
large, global phase 3 study, in which outcomes are 
generally expected to be less favourable than phase 2 
studies restricted to specialised centres. Thus, it is more 
likely that optimisation of standards of care has promoted 
improvements in outcome over time (appendix p 8).17
In view of the negative result for the primary analysis 
and in accordance with the study’s sequential analysis 
plan, all subsequent analyses should be considered 
exploratory and cannot be interpreted as conclusive. 
However, an exploratory analysis showing a potential 
long­term (2­year) survival benefit in patients with SRD 
given rindopepimut versus control is an interesting 
result that does deserve discussion. No imbalances were 
identified that might have accounted for this signal 
of differential activity, since baseline prognostic 
characteristics, corticosteroid dosing, and subsequent 
therapies were well balanced between both treatment 
groups. Yet, this apparent treatment effect in the SRD 
population was less pronounced when tumour burden 
was defined by the investigator as opposed to central 
review, and the magnitude of humoral immune response 
did not consistently correlate with presumed treatment 
benefit or extent of residual disease. Although further 
study is needed, this exploratory finding might challenge 
the view that minimal tumour burden is required for 
immunotherapy to be most effective.
In the ReACT study,16 in which patients were not 
required to have MRD, rindopepimut was associated 
with a survival advantage (HR 0·53, 95% CI 0·32–0·88; 
p=0·013) when combined with bevacizumab. Although 
humoral responses were similar in patients in the ACT 
IV study irrespective of the amount of residual tumour 
present, whether effective cellular responses occurred in 
these patients is unclear. Perhaps residual disease, which 
would be associated with increased EGFRvIII expression, 
Rindopepimut plus temozolomide (n=369) Control plus temozolomide (n=372)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
(Continued from previous page)
Other skin and subcutaneous 
tissue disorders
72 (20%) 1 (<1%) 1 (<1%) 0 95 (26%) 2 (1%) 0 0
Other metabolism and nutrition 
disorders
45 (12%) 17 (5%) 3 (1%) 0 56 (15%) 15 (4%) 3 (1%) 0
Eye disorders 60 (16%) 2 (1%) 0 0 70 (19%) 4 (1%) 0 0
Renal and urinary disorders 50 (14%) 6 (2%) 1 (<1%) 0 59 (16%) 5 (1%) 0 0
Vascular disorders 37 (10%) 9 (2%) 4 (1%) 0 40 (11%) 14 (4%) 2 (1%) 0
Other blood and lymphatic 
system disorders
34 (9%) 6 (2%) 3 (1%) 0 29 (8%) 6 (2%) 2 (1%) 1 (<1%)
Ear and labyrinth disorders 32 (9%) 2 (1%) 0 0 45 (12%) 0 0 0
Cardiac disorders 14 (4%) 3 (1%) 1 (<1%) 1 (<1%) 19 (5%) 0 1 (<1%) 2 (1%)
Reproductive system 
and breast disorders
16 (4%) 2 (1%) 0 0 14 (4%) 0 0 0
Endocrine disorders 10 (3%) 2 (1%) 0 0 18 (5%) 1 (<1%) 0 0
Neoplasms 11 (3%) 0 0 0 6 (2%) 2 (1%) 1 (<1%) 0
Hepatobiliary disorders 0 1 (<1%) 0 0 3 (1%) 4 (1%) 0 0
Data are grade 1–2 adverse events occurring in ≥10% of patients in either group and all grade 3–5 adverse events in the safety population (all patients who received at least 
one dose of study treatment irrespective of tumour burden). 
Table 2: Adverse events
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is required to generate effective and persistent cellular 
immunity required for a therapeutic effect. The choice of 
combination treatment might also account for what 
seems to be a more prominent treatment effect in the 
ReACT study than that which might have occurred in the 
SRD population in ACT IV. VEGF is known to depress 
tumour immunity and bevacizumab has enhanced 
immune­mediated antitumour effect in non­clinical 
models.18 Alternatively, temozolomide­induced lympho­
penia might reduce the efficacy of an immunotherapy. 
However, this concept is not supported by the ACT II 
study, in which patients who received dose­intensified 
temozolomide with rindo pepimut developed more 
robust EGFRvIII­specific humoral immune responses, 
despite more substantial lymphopenia.
An unexpected finding was the loss of EGFRvIII 
expression in about 60% of the small subset of patients 
with tumour tissue available at recurrence, irrespective 
of study treatment received. Loss of EGFRvIII 
expression has been reported in most patients given 
rindopepimut,6,8,9 but not in those receiving standard­of­
care chemo radiation.19 However, contemporary datasets 
are contradictory. One RNA­only­based study reported 
frequent loss of EGFRvIII expression with standard 
therapy,20 but this was not confirmed in a recent study 
by the German Glioma Network.21 Although screening 
in ACT IV was done by PCR whereas previous 
studies used immunohistochemistry, the methods 
have previously shown good concordance.6 Supposing 
that the true rate of EGFRvIII loss at recurrence 
approaches 50%, one might conclude that the survival 
benefit recorded in the ReACT trial is derived from only 
half of the patients, and would therefore probably be 
quite significant in a cohort with confirmed EGFRvIII 
expression. More importantly, these data suggest that at 
least a biopsy is required to verify EGFRvIII positivity 
before patients with recurrent glioblastoma are enrolled 
into future trials targeting this mutation. However, the 
ACT IV results, as well as the lack of stability of 
EGFRvIII and its expression pattern restricted to 
subpopulations of tumour cells,5,21 raise questions about 
its role as a molecular target for treatment in primary 
glioblastoma. Trials with other agents in patients with 
EGFRvIII­mutated tumours might provide additional 
insight and clarity.
To our knowledge, ACT IV was the most comprehensive 
study of patients with EGFRvIII­expressing glioblastoma 
done so far, despite the fact that nearly half of eligible 
patients declined study participation, probably partly due 
to the nature of the screening process that allowed for an 
abbreviated “tissue screening” consent, followed later by 
the formal study evaluation and consenting process. 
However, limitations of the study include uncertainties 
about the significance of the cutoff of EGFRvIII expression 
for inclusion, and the fact that, because of practical 
considerations related to patient accrual (that patients 
would not be identified and screened in time to start 
study prior to radiation), the vaccine was started after 
radiotherapy rather than as early as possible. Furthermore, 
whether concurrent chemotherapy with temozolomide 
blunts the potential activity of immunotherapy remains 
controversial. There are some old and some new lessons 
to be learned from the disappointing outcome of ACT IV. 
First, even carefully assembled historical controls can be 
misleading and an unsuitable basis for clinical trial 
designs, because it is difficult to control for patient 
selection. Second, even biologically matching data of 
EGFRvIII loss at progression on anti­EGFRvIII treatment 
need controls. Third, because the humoral response to 
EGFRvIII was similar to that recorded in previous studies 
of rindopepimut, the present study does not support these 
responses as a reliable predictor of outcome and calls for 
intensified efforts to establish cellular immune responses 
as a read­out. Fourth, the selection of one molecular target 
of immunotherapy might be insufficient, especially if 
its expression is not stable and not ubiquitous, and 
multipeptide vaccines against several targets and non­
peptides with higher immunogenicity might turn out to be 
superior. Moreover, the most promising approach seems 
to be to combine a glioma­specific stimulus based on well 
defined antigens with a general activation of the immune 
system. At present, this can most easily be achieved with 
checkpoint inhibition or with the neutralisation of strong 
immunosuppressive factors such as TGF­β. Taken 
together, the results of the ACT IV and ReACT trials 
support the design of innovative clinical trials evaluating 
combination approaches to show efficacy of immuno­
therapy in glioblastoma.
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